ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 22, 2017
Investing Versus Speculating: Ford, GM, Tesla
Ford is making some changes at the top, but we still like General Motors. Tesla’s stock remains “uninvestable,” in our view.
May 20, 2017
Shoe Retailing Stocks Stumble
The market didn’t like the smell of Foot Locker’s first-quarter report, released May 19. Finish Line and Dick’s Sporting Goods likely forewarned of trouble.
May 20, 2017
Deere Runs! South America Not As Bad?
Deere’s equity is charging higher. Let’s look at the reasons why. Will Caterpillar follow?
May 20, 2017
Walmart Comes Roaring Back; Target Is Still Suffering
Image Source: Mike Mozart. Walmart and Target have taken a few body blows from Amazon, but the fight is far from over. Walmart is executing much better than Target at the moment.
May 18, 2017
Earnings Update on the Medical Devices Industry Featuring Zimmer Biomet, Edwards Lifesciences, and Intuitive Surgical
Image Source: Biomet Zimmer. The outperformance of the medical devices industry continues unabated in 2017. The momentum underscores that the steep sell-off in the second half of 2016 was likely an overreaction. We’re updating our previous take of Zimmer Biomet, along with a brief earnings update on Edwards Lifesciences and Intuitive Surgical.
May 18, 2017
Brazil: Sorry For Your Losses
The Brazilian equity markets are in free fall.
May 18, 2017
ETF Analysis: Utilities
Utilities sector ETFs diversify away firm-specific regulatory uncertainty, geographic concentration risk, and the unregulated business volatility of any one particular operator.
May 17, 2017
Volatility Spikes, Oh Cisco, the Mighty US Dollar, and More
Image Source: CBOE. Let’s talk about recent market events May 17. There’s a lot going on.
May 17, 2017
Coherus Biosciences Begins the Process of Bringing a Humira Biosimilar to Market
Image Source: Drugs.com. The duration and validity of patents that back the intellectual property of drugs in the pharma/biotech industry underpin the group’s revenue stream. Once patent protection is lost, however, revenue from products typically nosedives as multi-source products come to market, undercutting their original price. The patent estate, in essence, bestows monopoly-like pricing power to Big Pharma. Once lost though, it becomes tough to replace. Let’s provide a quick update on the breaking Coherus Biosciences patent win.
May 17, 2017
Alert: Adding Protection! Finally Acting on Netflix Idea
Image Source: Esther Vargas. We’re adding protection to the newsletter portfolios and finally making a move on Netflix.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.